Meteo.gr reports strong weight loss results for amycretin, Novo Nordisk's next obesity candidate. Few details were given beyond the headline.
Recap by typeshit. Full story at Meteo.gr.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
A short Philstar Life item on PIONEER 8, a trial of oral semaglutide. The material gives only the title, so tap through for the details.
She points out one trial enrolled people with diabetes and the other excluded them, so the results aren't a head to head match.
Polskie Radio reports a Wegovy price cut in China, coming soon after the drug's approval there. Tap through for the details.
A brief Polskie Radio item on whether Mounjaro is FDA approved for weight loss. Little detail is available beyond the topic itself.
Loading…